GSK - GlaxoSmithKline plc (via Public) / Preclinical data de

GSK - GlaxoSmithKline plc (via Public) / Preclinical data demonstrate sotrovimab retains activity against key Omicron mutations, new SARS-CoV-2 variant

GSK - GlaxoSmithKline plc (via Public) / Preclinical data demonstrate sotrovimab retains activity against key Omicron mutations, new SARS-CoV-2 variant
publicnow.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from publicnow.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , Australia , Japan , United Kingdom , Singapore , Saudi Arabia , United Arab Emirates , Canada , Switzerland , Hal Barron , George Scangos , Glaxosmithkline , Vir Biotechnology Inc , Co Ltd , Monoclonal Antibody Administration , European Commission , World Health Organization , Committee For Human Medicinal Products , Drug Administration , European Medicines Agency For Xevudy , Nasdaq , Company Annual Report On Form , Medicago Inc , Vir Biotechnology , Chief Executive Officer , Chief Scientific Officer , Delta Plus , New England Journal , Human Medicinal Products , Special Approval , Marketing Authorisation Application , European Medicines Agency , United Arab , Joint Procurement Agreement , Fact Sheets , Fact Sheet , Healthcare Providers , Emergency Use Authorization , Including Anaphylaxis , Emergency Use , Annual Report , Gsk Glaxosmithkline Plc Via Public Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations , New Sars Cov 2 Variant ,